What Is Setmelanotide?
Setmelanotide is an FDA-approved peptide medicine sold as Imcivree by Rhythm Pharmaceuticals. The label describes it as an 8-amino-acid cyclic peptide analog of α-MSH, a natural brain hormone. It is given as a subcutaneous injection. First US approval was in 2020.
It works as an agonist at the melanocortin-4 receptor (MC4R). MC4R sits in the hypothalamus and helps control hunger and energy balance. Setmelanotide has about 20-fold less activity at the related MC1 and MC3 receptors.
Setmelanotide is not a general weight-loss drug. It is approved only for specific conditions in which the MC4R pathway is broken upstream of the receptor. This page is educational and contains no dosing guidance.
Why MC4R Matters
The hypothalamus reads signals like leptin and turns them into a "satiety" message through a chain of steps:
- Leptin binds the leptin receptor (LEPR).
- Neurons make POMC, a precursor protein.
- Enzymes such as PCSK1 cut POMC into α-MSH.
- α-MSH activates MC4R, which reduces hunger.
If a genetic variant breaks an earlier step, or a tumour, surgery or injury damages the hypothalamus, the signal never reaches MC4R. People can have intense, persistent hunger (hyperphagia) and severe early-onset obesity. Setmelanotide stands in for the missing α-MSH signal at the receptor.
GLP-1 drugs like semaglutide and tirzepatide act on different, gut-hormone receptors. That's why setmelanotide is a different tool, not a substitute.
What FDA Has Approved
Per the current Imcivree label (revised April 2026), setmelanotide is indicated to reduce excess body weight and maintain weight reduction long term in:
| Condition | Age | Notes |
|---|---|---|
| Acquired hypothalamic obesity (HO) | 4 years and older | Added to the label in March 2026 |
| Bardet-Biedl syndrome (BBS) | 2 years and older | Rare genetic ciliopathy |
| POMC, PCSK1 or LEPR deficiency | 2 years and older | Confirmed by genetic testing showing pathogenic, likely pathogenic, or uncertain-significance variants |
Diagnosis and genetic testing are required. Common obesity without one of these causes is not an approved use.
What the Trials Showed
Acquired hypothalamic obesity: TRANSCEND (NEJM, July 2026)
Acquired HO usually follows a brain tumour such as craniopharyngioma, or its treatment. It is notoriously hard to treat with diet, exercise or standard drugs.
TRANSCEND was a randomized, double-blind, placebo-controlled phase 3 trial (NCT05774756) in participants aged 4 to 66 with acquired HO.
- 120 participants were randomized 2:1 (81 setmelanotide, 39 placebo).
- After 52 weeks of treatment, mean BMI changed by -16.5% with setmelanotide versus +3.3% with placebo (P < 0.001).
- Weekly maximal hunger scores (0–10 scale, ages 12 and up) fell by 2.73 points versus 1.45 with placebo (P = 0.009).
- Adverse events occurred in 100% of the setmelanotide group and 90% of the placebo group. Serious adverse events occurred in 28% versus 8%.
- The most common adverse events were skin hyperpigmentation, nausea, vomiting and headache.
Genetic obesity and BBS (from the label)
- POMC or PCSK1 deficiency: 80% of patients (8 of 10) reached at least 10% weight loss, the primary endpoint.
- LEPR deficiency: 46% of patients (5 of 11) reached at least 10% weight loss.
- Bardet-Biedl syndrome (patients 6 and older): in the 14-week placebo-controlled period, BMI changed by -4.6% versus -0.1% with placebo. After 52 weeks of open-label treatment, mean BMI change was -7.9% (N=31), and 38.7% achieved a BMI drop of 10% or more.
These were small trials, which is normal for rare diseases. Section 14 of the label describes each trial's design, including which ones had a placebo comparison.
Label Warnings and Side Effects
The Imcivree label has no boxed warning. Its warnings and precautions include:
- Sexual adverse reactions, including spontaneous penile erections in males. Erections lasting more than 4 hours need emergency care.
- Depression and suicidal ideation. Patients should be monitored for new or worsening mood symptoms.
- Hypersensitivity, including anaphylaxis.
- Skin pigmentation: generalized darkening, darkening of existing moles, and new moles. The label calls for full-body skin exams.
- Acute adrenal insufficiency in hypothalamic obesity (5% on setmelanotide, 0% on placebo in the HO trial).
- Sodium changes in HO patients with diabetes insipidus.
Common adverse reactions (20% or more in at least one indication) include skin hyperpigmentation, injection-site reactions, nausea, headache, diarrhea, abdominal pain, vomiting, depression and spontaneous penile erection.
